Expression of selected genes involved in transport of ions in papillary thyroid carcinoma;Ekspresja wybranych genów zaangażowanych w transport jonów w raku brodawkowatym tarczycy

Endokrynologia Polska

Volumn 57, Issue SUPPL.A, 2006, Pages

  Gałȩza Kulik, Monika ^a   Zebracka, Jadwiga ^a   Szpak Ulczok, Sylwia ^a   Krawczyk, Aleksandra ^a   Czarniecka, Agnieszka ^a   Kukulska, Aleksandra ^a   Gubała, Elzbieta ^a   Stojcev, Zoran ^a   Wiench, Małgorzata ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Gene expression; Papillary thyroid carcinoma; Realtime quantitative PCR

Indexed keywords

SLC34A2 PROTEIN, HUMAN; SODIUM PHOSPHATE COTRANSPORTER 2B; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIB; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 72449143989     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Santaro M, Carlomagno F, Hay ID i wsp. Ret oncogene activation in human thyroid neoplasm is restricted to the papillary cancer subtype. J Clin Invest 1982; 89: 1517-1522.
2. Wiench M, Wloch J, Oczko M i wsp. Rearrangement of the RET gene in papillary thyroid carcinoma. Wiad Lek 2001; 54 (supl. 1): 64-71.
3. Jarza̧b B. Leczenie raka tarczycy. Endokrynol Pol 1995; 46: 25-35.
4. Cohen Y, Xing M, Mambo E i wsp. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003.
5. Huang Y, Prasad M, Lemon WJ i wsp. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci, USA 2001; 98 (26): 15044-15049.
6. Jarza̧b B, Wiench M, Fujarewicz K i wsp. Gene expression profile of papillary thyroid cancer: Sources of variability and diagnostic implications. Cancer Res 2005; 65 (4): 1587-1597.
7. Lopes CM, Zhang H, Rohacs T i wsp. Alterations in conserved Kir channel-PIP(2) interactions underlie channelopathies. Neuron 2002; 34: 933-944.
8. Donaldson MR, Jensen JL, Tristani-Furouzi M i wsp. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 2003; 60: 1811-1816.
9. Andelfinger G, Tapper AR, Welch RC i wsp. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotype. Am J Hum Genet 2002; 71: 663-668.
10. Soleimani M, Burnham CE. Physiologic and molecular aspects of the Na+:HCO3- cotransporter in health and disease processes. Kidney Int 2000; 57 (2): 371-384.
11. Igarashi T, Inatomi J, Sekine i wsp. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nature Genet 1999; 23: 264-265.
12. Feild JA, Zhang L, Brun KA i wsp. Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine. Biochem Biophys Res Commun 1999; 258 (3): 578-582.
13. Prasad ML, Pellegata NS, Kloos RT i wsp. CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 2004; 14 (3): 169-175.
14. Bidart JM, Lacroix L, Evan-Brion D i wsp. Expression of Na+//I- symporter and Pendred syndrome genes in trophoblast cells. J Clin Endocrinol Metab 2000; 85: 4367-4372.
15. Arturi F, Russo D, Bidart JM i wsp. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 2001; 145: 129-135.